In the media
News
Partner Organisations
Call to Action - "Immunisation for a Resilient Europe: From EU Commitment to National Action" (MBVE)
A call to EU institutions and Member States
A new study finds that to counter misinformation online, we need to copy its style
Reporting on a paper published in the Journal of Computational Science in September 2026.
Adult Respiratory Vaccination Delivers Up to $12 in Societal Value for Every $1 Spent, Analysis Finds
Benefit-cost modeling estimated $22B annual spend produces $101B-$241B net benefits, preventing ~18,500 deaths and 300,000 hospitalizations in a single year.
Beyond childhood: why lifelong vaccination is a frontline defence against chronic disease
Guest article by the World Federation of Public Health Associations (WFPHA)
Strengthening the EU’s Medical Supply Chains
International Co-operation and New Technologies for Better Emergency Preparedness
mRNA-based influenza vaccine expands the B cell response breadth in humans
These findings reveal a key role for persistent germinal center responses in broadening the repertoire of vaccine-induced antibodies.
Effectiveness of nirsevimab immunisation on invasive pneumococcal disease in children nationwide in France: an observational cohort study
These findings suggest an additional benefit of nirsevimab implementation beyond RSV disease prevention, but further studies are needed.
Recombinant Influenza Vaccine and Influenza Outbreaks in US Nursing Homes: Results From a Pragmatic Cluster-Randomized Clinical Trial
These findings suggest that recombinant influenza vaccines may provide clinically meaningful facility-level benefits in long-term care settings during seasons with substantial influenza circulation.
